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In Brief
The crystal structure of the primed Ebola virus glycoprotein in complex with domain C of the endosomal entry receptor Niemann-Pick C1 reveals structural insights into filovirus fusion to the late endosome and the molecular basis for designing therapeutic inhibitors of viral entry.
Accession Numbers 5F18 5F1B

INTRODUCTION
The filovirus family Filoviradae, including the genera Ebolavirus and Marburgvirus, can cause a rapidly lethal hemorrhagic fever in humans, and at present, no clinically approved antiviral therapeutics are available. Since 1967, Marburg virus has emerged multiple times, with modern strains showing greater mortality Malherbe and Strickland-Cholmley, 1968; Siegert et al., 1968; Towner et al., 2006) . The Ebolavirus consists of five recognized species, including Zaire, Sudan, Reston, Bundibugyo and Tai Forest viruses, four of which (except the Reston virus) can infect humans (Kuhn et al., 2013; Kuhn and Jahrling, 2010) . Among these filoviruses, Ebola virus (EBOV) and the Marburgvirus (MARV) Angola variant cause the most severe diseases, with case fatality rates reaching 90% (Feldmann and Geisbert, 2011; Sullivan et al., 2009) . Recently, since December 2013, a historically unprecedented EBOV outbreak has occurred in the West Africa, causing more than 25,000 human infections and over 10,000 related deaths as of May 18 th , 2015 . Under this urgent situation, we are called for great efforts to develop the vaccines and antiviral therapeutics, which needs a comprehensive and decent understanding of the pathogenesis and molecular basis of EBOV infection. Regarding the infection by filoviruses, including EBOV, the primarily infected cells are macrophages and dendritic cells. But the viruses exhibit a much broader cell tropism and can infect, upon primary infection, most of the cell types, including epithelial and non-epithelial cells, with the exception of lymphocytes and other non-adherent cells (Dube et al., 2010) . Host cell attachment factors such as C-type lectins, including DC-SIGN (dendritic-cell-specific ICAM3-grabbing non-integrin; also known as CD209) and L-SIGN (liver and lymph node SIGN; also known as CLEC4M) and several cell-surface proteins such as integrins, T cell immunoglobulin and mucin domain-containing (TIM) proteins, and tyrosine protein kinase receptor 3 (TYRO3) family members have been shown to mediate the entry of filoviruses on the cell surface (Alvarez et al., 2002; Jemielity et al., 2013; Kondratowicz et al., 2011; Shimojima et al., 2007; Simmons et al., 2003; Takada et al., 2000 Takada et al., , 2004 Wang et al., 2015) . These attachment factors, however, do not function as authentic entry receptors Schornberg et al., 2009) . Following binding to the cell surface, filoviruses are internalized by a macropinocytosis-like process and subsequently trafficked through early and late endosomes Nanbo et al., 2010; Saeed et al., 2010) . The viral genome then penetrates into the cytoplasm after fusion of the viral envelope with the membrane of the late endosome. In the cytoplasm, the viral genome is replicated and transcribed, and new viral proteins are synthesized to assemble progeny virions, which bud from the cell surface (Bharat et al., 2011; Feldmann et al., 2013) . Given its place at the initial step of virus infection, the entry process represents an ideal target for antiviral intervention: stopping the virus before it enters the cell.
The trimeric glycoprotein (GP) spike on the envelope of filoviruses mediates all stages of virus entry, including attachment, entry, and fusion (Lee and Saphire, 2009) . Like all the other Class I viral fusion proteins, the EBOV GP is synthesized as a single polypeptide that is subsequently cleaved by furin-like proteases into GP1 and GP2 subunits, which remain together through an inter-subunit disulfide bond and non-covalent interactions. In contrast to other Class I viral fusion proteins, however, the simple furin cleavage event is not sufficient to prime EBOV GP (Neumann et al., 2007; Wool-Lewis and Bates, 1999) . After entering into the cell, the virus is eventually trafficked to late endosomes, where GP is further primed to remove some ''cap'' components, thereby triggering the induction of the crucial membrane fusion event, which leads to viral penetration. The functional EBOV GP priming is mediated by the cysteine proteases cathepsin B and cathepsin L (Chandran et al., 2005; Schornberg et al., 2006) , which cleave GP1 within the b13-b14 loop Hood et al., 2010; Lee et al., 2008) . Cathepsin cleavage removes 60% of the amino acids from GP1, including the mucin-like domain, the glycan cap, and the outmost b strand of the proposed receptor binding region Lee et al., 2008) , resulting in a primed form of GP (named GPcl, the 19 kDa GP1 plus GP2) ( Figure 1A ). Unlike the full-length GP, the primed GPcl could bind to an endosomal membrane protein Niemann-Pick C1 (NPC1) (Miller et al., 2012) , which is an indispensable host entry factor for EBOV infection (Carette et al., 2011; Cô té et al., 2011) . NPC1 is a ubiquitously expressed protein with multiple transmembrane domains and resides primarily in the limiting membranes of late endosomes and lysosomes (Carstea et al., 1997; Davies and Ioannou, 2000) . It functions to aid cholesterol egress out of late endosomes for re-distribution to cellular membranes (including endoplasmic reticulum and plasma membrane) in the assistance of a soluble NPC2 protein (Sleat et al., 2004) . Further studies have revealed that the second luminal domain (Domain C) of NPC1 (NPC1-C) is responsible for the binding to GPcl ( Figure 1A ) (Miller et al., 2012) . However, how GPcl binds to NPC1 remains elusive, and structural study should be carried out to investigate the molecular features of the binding interface, which will guide further development of small antiviral molecules and antibodies for prevention and/or treatment of EBOV infection.
Here, we have determined the crystal structures of free NPC1-C and its complex with GPcl. The results revealed that NPC1-C displays a helical structure core surrounded by several b strands and contains two extended loops protruding outward for ligand interactions. Further GPcl/NPC1-C complex structure indeed shows that NPC1-C utilizes the two protruding loops to engage a hydrophobic cavity on the head of GPcl. Despite a low affinity between NPC1-C and GPcl as revealed by the biophysical analyses, upon enzymatic cleavage and NPC1-C binding, several conformational changes are shown to be induced in GPcl. After conformational changes, the uplift of the short 3 10 helix in the b3-a1 loop likely helps to release the N-terminal portion of the internal fusion loop (IFL), thereby triggering the membrane fusion. The mutagenesis work in NPC1-C further confirmed that Table S1 .
the protruding loop 2 plays a more important role in the binding of NPC1-C to GPcl.
RESULTS
Structure of NPC1-C The 1,278 residue human NPC1 contains 13 predicted transmembrane-spanning helices and 3 large luminal domains, domains A, C, and I ( Figure 1A ), the overall structural features of which remain to be illustrated. The crystal structure of the first luminal domain (domain A, also called N-terminal domain, NTD) is previously reported, showing a helical structural fold that contains a deep pocket for binding of sterols (Kwon et al., 2009) . The structure information of the second and third luminal domains (domains C and I, respectively) of NPC1, however, are uncharacterized. Here, we used the pET21a expression vector to produce human NPC1-C (residues 374 to 620) in E. coli BL21 (DE3), and the protein exists as insoluble inclusion bodies. Then the inclusion bodies were refolded to obtain soluble NPC1-C, which behaves as a single monomeric peak in gel filtration ( Figure S1A ). Some droplet-like crystals were obtained using the sitting drop vapor diffusion crystallization method, and the best crystal diffracted to a high resolution of 2.0 Å . As there is no homology structural model, the crystal structure of NPC1-C was determined by using single wavelength anomalous dispersion (SAD) phasing method with the help of a gold derivative. After several rounds of refinement, the final R free and R work reached 21.9 and 18.2, respectively (Table S1 ). Overall, NPC1-C is mainly composed of seven a helices in the center as a core and seven b strands surrounding the core, with two protruding loops ( Figure 1B ). The first protruding loop (loop 1) is localized between b2 and b3 strands, while the second protruding loop (loop 2) is between a4 and a5 helices ( Figure 1B ). NPC1-C contains four cysteine residues, all of which were involved in forming disulfide bonds (C468-C479, C516-C533) ( Figure 1C ). Through analysis of primary protein sequence, NPC1-C has seven potential N-linked glycosylation sites, six of which locate in the loops, while one locates at the tip of a4 helix ( Figure S1B ). No glycans are observed in the crystal structure because the NPC1-C protein is expressed in bacterial cells that lack post-translational glycosylation modifications. However, the surface exposure of the seven sites indicates their accessibility for N-glyco-transferases.
The intact luminal NPC1-C consists of residues 372 to 640. In our crystal structure, only residues 384 to 624 are visible (Figure S2) . We cannot see the electron density for the N-terminal 12 amino acids and C-terminal 16 amino acids ( Figure S2 ), indicating that these regions might be flexible loops. It is assumed that, with these flexible N-terminal and C-terminal loops, the domain C can protrude from the endosomal membrane (Figure S3) and be easily bound by the primed GP molecule.
NPC1-C Bound to the GPcl with a Low Affinity
The mucin-deleted ectodomain of EBOV GP (GP-ectoDmucin) was expressed in insect cells using baculovirus expression system and purified as a single homotrimeric peak by gel filtration ( Figure S4A ) following the previously reported method (Lee et al., 2008) . Subsequently, thermolysin was used to cleave the GP-ecto protein to obtain GPcl, which also exists as a similar homotrimeric peak with relatively smaller size in the gel filtration ( Figure S4A ), following the previously developed method . The thermolysin, a protease that functions at neutral pH, can substitute for the cathepsin enzymes in priming GP (Schornberg et al., 2006) . As expected, GP1 is cleaved into a 19 kDa protein moiety after thermolysin digestion ( Figure S4A ), resembling the version of GP component responsible for receptor binding in the endosome.
In order to test the active interactions between purified NPC1-C and GPcl proteins, we performed surface plasmon resonance (SPR) experiments to explore the binding affinity of these two proteins using a BIAcore 3000 instrument. The GPectoDmucin or GPcl protein was immobilized on a CM5 chip, which was then flown through with the NPC1-C protein. Before we tested the NPC1-C protein, we first used 2G4 antibody (a member of the ZMapp cocktail (Qiu et al., 2014) , which shows active binding capacity to the stem region of EBOV GP protein) as a positive control, confirming that the GP-ectoDmucin and GPcl protein on the chip remain in the native prefusion state (Figure S4B) . We found that 2G4 binds to GP-ectoDmucin and GPcl protein with similar binding affinities (8.2 nM versus 3.8 nM) ( Figure S4B ). As expected, GP-ectoDmucin does not bind to NPC1-C (Figure 2A ), while GPcl binds to NPC1-C with a low affinity of 158 micromolar (mM) (Figures 2B and 2C) . This binding affinity is much lower than that of some other highly pathogenic viruses such as MERS-CoV and SARS-CoV, which is among the nanomolar (nM) range (Lu et al., 2013) .
In order to evaluate effect of the glycosylations in NPC1-C protein on binding of GPcl, we expressed glycosylated NPC1-C protein in 293T mammalian cells. This glycosylated NPC1-C protein exists as a dispersing band in the SDS-PAGE with an average molecular weight of about 55 kDa ( Figure S5 ). Further SPR experiments revealed that the glycosylated NPC1-C does not bind to GP-ectoDmucin ( Figure 2D ) but binds to GPcl with a comparable low affinity of 140 mM ( Figures 2E and 2F ) to the refolded NPC1-C protein (158 mM). It indicates that the glycosylations in NPC1-C have no effect on the binding of GPcl.
Complex Structure of NPC1-C and GPcl
The NPC1-C and GPcl were incubated together at a molar ratio of 1:1, and then crystallization screen was performed with the mixed protein complex. Initially, low-resolution-diffractive crystals were obtained, and after optimization of crystallization condition, a high-resolution-diffractive dataset was finally collected at the synchrotron facility. The complex structure was determined by molecular replacement at a resolution of 2.3 Å .
Structural analysis of the bound GPcl demonstrates that the cathepsin enzymes indeed cleave the GP protein within the b13-b14 loop ( Figure 3A) , and only residues 31 to 188 of GP1 subunit and residues 509 to 598 of GP2 subunit are visible in the crystal structure. After cathepsin cleavage, the glycan cap and mucin domain components would be removed ( Figure 3A) .
The solved complex structure reveals that NPC1-C binds the membrane-distal head of GPcl with a perpendicular angle (Figure 3B) . NPC1-C mainly uses its two protruding loops to engage a hydrophobic cavity in the head of primed GP1 ( Figure 3B ). The hydrophobic cavity was formed by residues from the a1 helix, the b4, b7, b9, and b10 strands, and the b9-b10 and b12-b13 loops ( Figure 3B ). The protruding loop 1 of NPC1-C contacts one side of the cavity, while the protruding loop 2 inserts into the cavity ( Figure 3B ). In the protruding loop 1, seven residues (Y420, Q421, Y423, P424, S425, G426, and D428) are involved in the interaction ( Figure 3C, top) , among which residues Y423 and P424 contribute most of the atom-to-atom contacts (Table 1 ). In the protruding loop 2, six residues (D501, D502, F503, F504, V505, and Y506) participate in the binding process ( Figure 3C , top), and residues F503, F504, and Y506 play the major role by contributing the majority of the tight hydrophobic interactions with the head cavity of GPcl (Table 1) . Moreover, residue D501 of NPC1-C forms a hydrogen bond with residue T83 of GPcl in the cavity ( Figure 3C and Table 1 ). Reciprocally, the hydrophobic cavity of GPcl consists of residues V79, P80, T83, W86, G87, F88, L111, E112, I113, V141, G145, P146, C147, A152, and I170, while the other residues of K114, G118, S142, G143, and T144 form a hydrophilic patch contacting the protruding loop 1 with polar interactions (Figure 3C , bottom). Of these polar contacts, the NPC1-C residue Q421 forms a hydrogen bond with the GPcl residue T144, and the NPC1-C residue D428 could form a potential salt bridge with GPcl residue K114 in the hydrophilic patch ( Figure 3C and Table 1 ).
Structural Comparison between GP and GPcl
Before GP is cleaved by the cathepsin enzymes, the binding site for NPC1-C is shielded by the glycan cap ( Figure 4A ). The b14 strand forms a hydrogen bond network with the b9 strand, and two aromatic residues F225 and Y232 insert into the hydrophobic cavity in the head of GPcl. By contrast, NPC1-C takes advantage of four aromatic residues (Y423, F503, F504, and Y506) and one hydrophobic residue P424 to interact with the hydrophobic cavity. Of special importance, residue F503 inserts into the cavity at a deeper position ( Figure 4B) . Thus, the binding of NPC1-C mimics the interaction between the glycan cap and the cavity but likely with a better binding capacity by providing more aromatic residues. Interestingly, a recent study revealed that a similar hydrophobic cavity is found in the primed Marburg virus GP protein, and the cavity can be targeted by a neutralizing antibody MR78 . MR78 binds to the cavity mainly through two aromatic residues F111.2 and Y112.2 (Figure 4C) , with a similar hydrophobic interaction in the binding of NPC1-C to GPcl.
Through comparison between the unbound GP and the NPC1-C-bound GPcl, several conformational changes are observed. Two most dominant changes occur in the binding site of NPC1-C, including the b7-b8 loop and the a1 helix. In reference to that in the unbound GP, the b7-b8 loop moves downward, whereas the a1 helix goes upward upon engagement with NPC1-C ( Figure 5A ). With the movement of the a1 helix, the short 3 10 helix in the b3-a1 loop raises upward correspondingly (Figure 5A ). In the unbound GP, residue N73 in the beta turn forms a hydrogen bond with the main-chain carboxyl oxygen of residue K510, which is in the N-terminal portion of the internal fusion loop (IFL) ( Figure 5B ). The interaction can compromise the electric repulsion between K510 and R559 (in the HR1 helix of GP2) (Figure 5B ). In the bound GPcl, due to the uplift of the short 3 10 helix, residue N73 does not interact with residue K510, and the side chain of K510 points inward and easily generates an electric repulsion with residue R559 ( Figure 5C ). The unfavorable interaction likely helps to release the IFL and therefore make ready to trigger the membrane fusion in the late endosomes.
Mutagenesis Confirms the Key Interaction Residues
In order to clarify the interactions between the NPC1-C and GPcl, we performed mutagenesis work with NPC1-C and used the SPR experiment to test the binding. The structural analyses in the above section revealed that residues Y423, P424, F503, F504, and Y506 play the major role by contributing most of the interactions. Thus, we substituted these five sites with alanine (A) or glycine (G) residues, including quintuple substitution, double substitution (Y423&P424 or F503&F504), and single substitution. Unfortunately, the quintuple-A mutant (Y423A&P424A& F503A&F504A&Y506A), double mutant (Y423A&P424A), and two of the single mutants (Y423G and Y506G) cannot be refolded ( Figures S6 and S7 ). As expected, the quintuple-G substitution (Y423G&P424G&F503G&F504G&Y506G) in NPC1-C abolishes its binding to GPcl ( Figure 6A ). The double mutant in loop 1 (Y423G&P424G) dramatically reduces the binding affinity, and the double mutants (both F503A&F504A and F503G&F504G) abolish the binding (Figures 6B-6D ). The single mutants in loop 2 (F503G, F504G, F503A, F504A, and Y506A) similarly abolish the binding to GPcl, as observed for the quintuple mutant (Figures 6E-6I) . However, the single mutants in loop 1 (P424G, Y423A and P424A) can keep the binding capacity to GPcl but with slightly lower affinities ( Figures 6J-6L) , compared with the wild-type NPC1-C. Taken together, the mutagenesis work points out that the protruding loop 2 contributes more to the GPcl binding.
DISCUSSION
Virus-cell membrane fusion is the means by which all enveloped viruses, including devastating human pathogens such as filovirus, influenza virus, and human immunodeficiency virus (HIV), enter cells and initiate the life cycle of virus infection (Backovic and Rey, 2012) . This membrane fusion process is executed by (B) Overall complex structure. The NPC1-C uses its two protruding loops to bind to the head of GPcl at a perpendicular angle. (C) Surface representations of interacting residues in the NPC1-C and GPcl. The residues responsible for the binding in the NPC1-C (top) are colored in blue, and the interacting residues in the GPcl (bottom) are colored in orange. The NPC1-C mainly utilizes aromatic residues to engage the cavity of the GPcl, which mainly consists of hydrophobic residues. See also Table S1. one or more viral envelope glycoproteins, including one that is generally defined as the fusion protein. As viral fusion proteins can mediate virus entry and genome release, leading to infection, they are increasingly exploited as targets for antiviral interventions (Harrison, 2015) . The fusion can occur either on the cell plasma membrane or endosomal membrane (Harrison, 2015) .
With major breakthroughs in our understanding of the proteins or protein complexes that mediate membrane fusion between enveloped viruses and their host cells, the fusion trigger can be classified into four major types: (1) interaction of the fusion protein with a cell-surface receptor; (2) sequential interactions with a cell-surface receptor and co-receptor/s; (3) exposure to low pH environment in endosomes after entering the cell by a general ''swallow'' process (e.g., endocytosis); and (4) sequential interactions with a cell-surface receptor followed by exposure to low pH environment in endosomes (White et al., 2008) . After fusion trigger, the fusion protein would undergo a series of marked conformational changes (White et al., 2008) . A key early event is the exposure of the fusion loop (or fusion peptide), which is otherwise either buried or fastened in the native fusion protein (Harrison, 2015; White et al., 2008) . When the fusion loop or fusion peptide is released, it binds to the target membrane, forming a rod-shaped intermediate, which connects the viral and target membranes. Next, the fusion protein bends approximately in half by conformational changes and draws the viral and target membranes into close proximity, finally resulting in the two membranes to merge (Harrison, 2015; Wang et al., 2005; White et al., 2008) .
It seems that EBOV fusion does not follow the abovementioned four types of fusion-trigger manners, and the viral GP needs first to be primed inside the endosome, after entering the cell by cell-surface receptor or co-factor induction, to expose its endosome-receptor binding domain for its fusion trigger (White et al., 2008) . There is an EBOV receptor residing in the endosome, and therefore a low pH environment is needed to facilitate conformational changes in the primed GP after its endosomal receptor binding (Brecher et al., 2012; Gregory et al., 2011; Schornberg et al., 2006) . It has been identified that the endosome-residing NPC1 is the endosome-receptor to bind to the primed GP (Carette et al., 2011; Cô té et al., 2011) . It has been shown that GP is processed by cathepsin L and B to yield a primed GP (GPcl) for its full function to trigger the membrane fusion (Chandran et al., 2005; Schornberg et al., 2006) . NPC1-C domain has been proposed to be the binding partner of the primed GP (Miller et al., 2012) .
In this study, we present the structural evidence that NPC1-C indeed binds to the primed EBOV GP, and SPR experiments reveal that the binding affinity is low. Since the binding affinity between individual NPC1-C and the primed GP is low, an obvious question raised here would be how the primed GP can efficiently bind to the endosomal receptor NPC. We can see that there are two possibilities: either the confinement in the late endosomes makes the local concentration of NPC1 to be very high, in which case a dissociation constant in the order of 100 mM would be sufficient, or that additional domains of NPC1 also contribute to the binding affinity. These possibilities or beyond should be pursued in the future.
The receptor binding region for NPC1-C is mainly a hydrophobic cavity in the head of the primed GP and is contacted by the two protruding loops of NPC1-C. Upon enzymatic cleavage and NPC1-C binding, we have observed several conformational changes in the GPcl, of which the upward movement of a short 3 10 helix in the b3-a1 loop likely helps to release the N-terminal portion of the IFL in the GP2 subunit, which is probably triggering the membrane fusion. As the crystal structure of free GPcl is not resolved yet, we do not know if it is cathepsin cleavage that induces a membrane-fusion-priming conformational change in GPcl or the binding of GPcl by NPC1-C. However, our data support the notion that there should be a fifth fusion triggering type, i.e., exposure to a low pH environment in the late endosome and interaction with an endosomal receptor. The Marburgvirus has a similar hydrophobic cavity in its head of the primed GP and also needs NPC1 for viral fusion (Carette et al., 2011; Cô té et al., 2011) . This fusion-triggering mechanism likely represents a unique feature for all the filoviruses. The structural data of the GPcl/NPC1-C complex have immediately pointed toward the development of therapeutic agents that target their binding interface as the strategies to treat infections by EBOV and other filoviruses. Previously, compounds have been found to potentially inhibit EBOV entry by targeting the NPC1 molecule (Cô té et al., 2011) . There are two classes of NPC1-interacting compounds that can hamper the filovirus entry and infection, typified by compound 3.47 and compound U18666A (Cô té et al., 2011) . The former compound was shown to competitively block the primed GP binding to the membrane (Cô té et al., 2011) , and according to our structural information, Numbers represent the number of atom-to-atom contacts between the GPcl residues and the NPC1-C residues, which were analyzed by the Contact program in CCP4 suite (the distance cutoff is 4.5 Å ).
this compound probably binds to the two protruding loops of NPC1-C, which should be explored in the future. By contrast, the latter compound cannot block the binding of primed GP to the NPC1-C but rather binding to a different site on NPC1 and causing endosomal calcium depletion, similar to other calcium channel inhibitors targeting the two-pore channels (TPCs) (Sakurai et al., 2015) . A full-length structure of NPC1 molecule is ideal to illuminate the true nature of the molecular basis of these inhibitors' effect, which should be pursued in the future, though we solved the NPC1-C domain structure in this study. In addition to designing inhibitors targeting NPC1, our data also provide another important direction for inhibitor design. By targeting the hydrophobic binding cavity in the head of the primed GP, some therapeutic agents, such as peptide inhibitors or small molecules, which can easily penetrate the cell membrane and reach the primed GP in the late endosomes, can be developed. Recently, a cross-reactive human antibody MR78 was identified to target this hydrophobic binding cavity of both MARV and EBOV . MR78 can neutralize the MARV but cannot neutralize the EBOV , which might result from the fact that the hydrophobic binding cavity of MARV GP is partially exposed, whereas the cavity of EBOV GP is fully shielded by glycan cap before cathepsin cleavage in the endosome. The antibody cannot easily penetrate the cell membrane and reach the primed GP in the late endosomes, whereas the peptide inhibitors and small molecules can execute it. These previous studies, together with our study, provide a map by which therapy with cross-reactive antibodies and small inhibitors of entry could be developed. Otherwise, recent research advances in the nucleoprotein and its chaperoned VP35 protein also provide key targets for therapeutic intervention (Dong et al., 2015; Kirchdoerfer et al., 2015; Leung et al., 2015) . In conclusion, our results presented in this study for the structural basis of primed EBOV GP bound to its endosomeresiding receptor NPC1 expand our understanding in the fusion trigger mechanism of enveloped viruses and provide valuable information for the design of therapeutics against infections by filoviruses.
EXPERIMENTAL PROCEDURES Protein Production and Crystallization
The cDNAs encoding domain C residues 374-620 of NPC1 were cloned into pET21a vector with a C-terminal His 6 -tag. The NPC1-C mutants were constructed by site-directed mutagenesis kit. The NPC1 domain C proteins (NPC1-C) were expressed in Escherichia coli strain BL21 (DE3) as inclusion bodies and then refolded in vitro using the method as previously described (Shi et al., 2011) . The refolded NPC1-C proteins were then concentrated and purified by gel filtration on a HiLoad 16/60 Superdex 75 PG column (GE Healthcare). The fully glycosylated NPC1-C protein was expressed in 293T cells using the pCDNA4.0 vector and purified by metal affinity chromatography using a HisTrap HP 5 ml column (GE Healthcare) and then further purified by gel filtration on a HiLoad 16/60 Superdex 200 PG column (GE Healthcare). The EBOV transmembrane-and-mucin-domains-removed GP (GP-ectoDmucin) protein was constructed as previously described (Lee et al., 2008) and expressed in baculovirus expression system using Sf9 cells (Shi et al., 2013; Stevens et al., 2004; Zhang et al., 2010) . Soluble GP-ectoDmucin protein was harvested from the culture supernatants by metal affinity chromatography and purified by gel filtration on a HiLoad 16/60 Superdex 200 PG column (GE Healthcare). To mimic endosomal protease cleavage and produce primed EBOV GP (GPcl), which was capable of NPC1 binding, 1 mg of EBOV GPectoDmucin protein was incubated with 5 mg thermolysin overnight and purified on a Superdex 200 column.
All the crystals were obtained by using the sitting drop vapor diffusion method with 1 ml protein mixing with 1 ml reservoir solution. Diffractive crystals of free NPC1-C protein were obtained in a condition consisting of 0.07 M sodium acetate trihydrate (pH 4.6), 5.6% (w/v) polyethylene glycol 4,000, and 30% (v/v) glycerol at the protein concentration of 5 mg/ml. Derivative crystals were obtained by soaking NPC1-C crystals overnight in mother liquor containing 1 mM KAuCl 4 .
To obtain the complex crystals of NPC1-C bound to GPcl, the individual proteins were in vitro mixed at a molar ratio of 1:1 and incubated at 4 C for about 2 hr before concentrating and being used for crystallization. The high-quality complex crystals were obtained in a reservoir solution of 15% (v/v) pentaerythritolpropoxylate, 0.2 M sodium chloride (pH 5.5), and 0.1 M MES-NaOH with a protein concentration of 10 mg/ml.
Data Collection and Structure Determination
For data collection, all crystals were cryo-protected by briefly soaking in reservoir solution supplemented with 20% (v/v) glycerol before flash-cooling in liquid nitrogen. All the datasets were processed with HKL2000 software (Otwinowski and Minor, 1997). The structure of NPC1-C was determined by the SAD method with anomalous signal method using Au derivative with SHELXD (Usó n and Sheldrick, 1999) and Phaser (Read, 2001 ). The complex structure was solved by molecular replacement method using Phaser with the solved NPC1-C structure and previously reported GP structure (PDB code, 3CSY) as the search models. The atomic models were completed with Coot (Emsley and Cowtan, 2004) and refined with phenix.refine in Phenix (Adams et al., 2010) , and the stereochemical qualities of the final models were assessed with PROCHECK (Laskowski et al., 1993) . Data collection, processing, and refinement statistics are summarized in Table S1 .
SPR Analysis
The SPR analysis was performed using a BIAcore 3000 machine with CM5 chips (GE Healthcare) at room temperature (25 C). All the proteins using in SPR analysis were exchanged to BIAcore buffer, consisting of 10 mM HEPES (pH 7.5), 150 mM NaCl, and 0.005% (v/v) Tween-20, via gel filtration. The WT and mutant NPC1-C proteins or antibody 2G4 were serially diluted to a serial of concentrations. The analytes were then used to flow over the chip surface with the response units measured. The binding kinetics was analyzed with the software BIAevaluation Version 4.1 using 1:1 Langmuir binding model.
ACCESSION NUMBERS
The crystal structures of NPC1-C and NPC1-C/GPcl complex have been submitted to Protein Data Bank with accession numbers PDB: 5F18 and PDB: 5F1B, respectively. 
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